nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—CYP2C8—Spironolactone—dilated cardiomyopathy	0.114	0.409	CbGbCtD
Ponatinib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0874	0.314	CbGbCtD
Ponatinib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0769	0.277	CbGbCtD
Ponatinib—Gastric haemorrhage—Spironolactone—dilated cardiomyopathy	0.0397	0.185	CcSEcCtD
Ponatinib—FGFR4—heart—dilated cardiomyopathy	0.00814	0.067	CbGeAlD
Ponatinib—BCR—cardiac ventricle—dilated cardiomyopathy	0.00732	0.0603	CbGeAlD
Ponatinib—BCR—myocardium—dilated cardiomyopathy	0.00689	0.0567	CbGeAlD
Ponatinib—FGFR1—myocardium—dilated cardiomyopathy	0.00613	0.0504	CbGeAlD
Ponatinib—FGFR3—heart—dilated cardiomyopathy	0.00556	0.0457	CbGeAlD
Ponatinib—Atrial flutter—Lisinopril—dilated cardiomyopathy	0.00535	0.025	CcSEcCtD
Ponatinib—TEK—cardiac ventricle—dilated cardiomyopathy	0.00531	0.0437	CbGeAlD
Ponatinib—TEK—myocardium—dilated cardiomyopathy	0.00499	0.0411	CbGeAlD
Ponatinib—BCR—heart—dilated cardiomyopathy	0.00481	0.0396	CbGeAlD
Ponatinib—FLT3—heart—dilated cardiomyopathy	0.00477	0.0393	CbGeAlD
Ponatinib—KDR—cardiac ventricle—dilated cardiomyopathy	0.00434	0.0357	CbGeAlD
Ponatinib—FGFR1—heart—dilated cardiomyopathy	0.00428	0.0352	CbGeAlD
Ponatinib—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00414	0.0193	CcSEcCtD
Ponatinib—BCR—cardiac atrium—dilated cardiomyopathy	0.00411	0.0338	CbGeAlD
Ponatinib—KDR—myocardium—dilated cardiomyopathy	0.00408	0.0336	CbGeAlD
Ponatinib—RET—heart—dilated cardiomyopathy	0.00383	0.0315	CbGeAlD
Ponatinib—LCK—heart—dilated cardiomyopathy	0.00383	0.0315	CbGeAlD
Ponatinib—Lethargy—Spironolactone—dilated cardiomyopathy	0.00369	0.0172	CcSEcCtD
Ponatinib—FGFR1—cardiac atrium—dilated cardiomyopathy	0.00366	0.0301	CbGeAlD
Ponatinib—KIT—myocardium—dilated cardiomyopathy	0.00362	0.0298	CbGeAlD
Ponatinib—TEK—heart—dilated cardiomyopathy	0.00349	0.0287	CbGeAlD
Ponatinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.00335	0.0276	CbGeAlD
Ponatinib—PDGFRA—heart—dilated cardiomyopathy	0.00316	0.026	CbGeAlD
Ponatinib—ABL1—myocardium—dilated cardiomyopathy	0.00315	0.0259	CbGeAlD
Ponatinib—SRC—heart—dilated cardiomyopathy	0.0031	0.0255	CbGeAlD
Ponatinib—TEK—cardiac atrium—dilated cardiomyopathy	0.00298	0.0245	CbGeAlD
Ponatinib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00296	0.0138	CcSEcCtD
Ponatinib—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00292	0.0136	CcSEcCtD
Ponatinib—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00288	0.0134	CcSEcCtD
Ponatinib—KDR—heart—dilated cardiomyopathy	0.00285	0.0235	CbGeAlD
Ponatinib—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00276	0.0129	CcSEcCtD
Ponatinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00266	0.0124	CcSEcCtD
Ponatinib—SRC—cardiac atrium—dilated cardiomyopathy	0.00265	0.0218	CbGeAlD
Ponatinib—KIT—heart—dilated cardiomyopathy	0.00253	0.0208	CbGeAlD
Ponatinib—KDR—cardiac atrium—dilated cardiomyopathy	0.00244	0.0201	CbGeAlD
Ponatinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.00221	0.0103	CcSEcCtD
Ponatinib—ABL1—heart—dilated cardiomyopathy	0.0022	0.0181	CbGeAlD
Ponatinib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00214	0.00997	CcSEcCtD
Ponatinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00209	0.00977	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00209	0.00973	CcSEcCtD
Ponatinib—Neck pain—Lisinopril—dilated cardiomyopathy	0.00206	0.00961	CcSEcCtD
Ponatinib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00206	0.00961	CcSEcCtD
Ponatinib—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00203	0.00949	CcSEcCtD
Ponatinib—Lethargy—Furosemide—dilated cardiomyopathy	0.00201	0.00937	CcSEcCtD
Ponatinib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00198	0.00922	CcSEcCtD
Ponatinib—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00198	0.00922	CcSEcCtD
Ponatinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00195	0.0091	CcSEcCtD
Ponatinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00193	0.00901	CcSEcCtD
Ponatinib—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00191	0.00891	CcSEcCtD
Ponatinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.00188	0.0155	CbGeAlD
Ponatinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00184	0.0086	CcSEcCtD
Ponatinib—Dehydration—Furosemide—dilated cardiomyopathy	0.00183	0.00854	CcSEcCtD
Ponatinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00179	0.00836	CcSEcCtD
Ponatinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00174	0.00812	CcSEcCtD
Ponatinib—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00171	0.00799	CcSEcCtD
Ponatinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00167	0.00778	CcSEcCtD
Ponatinib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00156	0.00727	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00153	0.00716	CcSEcCtD
Ponatinib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00153	0.00716	CcSEcCtD
Ponatinib—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00151	0.00703	CcSEcCtD
Ponatinib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00148	0.00692	CcSEcCtD
Ponatinib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00148	0.00689	CcSEcCtD
Ponatinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00143	0.00669	CcSEcCtD
Ponatinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.00143	0.00665	CcSEcCtD
Ponatinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00141	0.00656	CcSEcCtD
Ponatinib—ABCG2—heart—dilated cardiomyopathy	0.00139	0.0114	CbGeAlD
Ponatinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00138	0.00646	CcSEcCtD
Ponatinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.00137	0.00641	CcSEcCtD
Ponatinib—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00133	0.00623	CcSEcCtD
Ponatinib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00132	0.00616	CcSEcCtD
Ponatinib—Visual impairment—Furosemide—dilated cardiomyopathy	0.00131	0.00612	CcSEcCtD
Ponatinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.00127	0.00594	CcSEcCtD
Ponatinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.00126	0.00587	CcSEcCtD
Ponatinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00125	0.00584	CcSEcCtD
Ponatinib—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00124	0.0058	CcSEcCtD
Ponatinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.00124	0.00576	CcSEcCtD
Ponatinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00122	0.00568	CcSEcCtD
Ponatinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00122	0.00568	CcSEcCtD
Ponatinib—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00121	0.00566	CcSEcCtD
Ponatinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00119	0.00557	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00119	0.00554	CcSEcCtD
Ponatinib—Erythema—Furosemide—dilated cardiomyopathy	0.00119	0.00553	CcSEcCtD
Ponatinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.00119	0.00553	CcSEcCtD
Ponatinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.00118	0.00549	CcSEcCtD
Ponatinib—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00118	0.00549	CcSEcCtD
Ponatinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00115	0.00539	CcSEcCtD
Ponatinib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00115	0.00537	CcSEcCtD
Ponatinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00114	0.00534	CcSEcCtD
Ponatinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00114	0.00532	CcSEcCtD
Ponatinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.00113	0.00528	CcSEcCtD
Ponatinib—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00112	0.00523	CcSEcCtD
Ponatinib—Rash—Spironolactone—dilated cardiomyopathy	0.00112	0.00523	CcSEcCtD
Ponatinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00112	0.00523	CcSEcCtD
Ponatinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.00112	0.00521	CcSEcCtD
Ponatinib—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00112	0.00521	CcSEcCtD
Ponatinib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00112	0.00521	CcSEcCtD
Ponatinib—Headache—Spironolactone—dilated cardiomyopathy	0.00111	0.0052	CcSEcCtD
Ponatinib—Jaundice—Lisinopril—dilated cardiomyopathy	0.00111	0.00518	CcSEcCtD
Ponatinib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00111	0.00516	CcSEcCtD
Ponatinib—Anaemia—Furosemide—dilated cardiomyopathy	0.0011	0.00511	CcSEcCtD
Ponatinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00108	0.00502	CcSEcCtD
Ponatinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00107	0.00501	CcSEcCtD
Ponatinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.00106	0.00495	CcSEcCtD
Ponatinib—Nausea—Spironolactone—dilated cardiomyopathy	0.00106	0.00493	CcSEcCtD
Ponatinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00101	0.0047	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.001	0.00468	CcSEcCtD
Ponatinib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000987	0.00461	CcSEcCtD
Ponatinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000948	0.00443	CcSEcCtD
Ponatinib—Flushing—Lisinopril—dilated cardiomyopathy	0.000948	0.00442	CcSEcCtD
Ponatinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000947	0.00442	CcSEcCtD
Ponatinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000939	0.00438	CcSEcCtD
Ponatinib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000935	0.00436	CcSEcCtD
Ponatinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000927	0.00433	CcSEcCtD
Ponatinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000921	0.0043	CcSEcCtD
Ponatinib—Chills—Lisinopril—dilated cardiomyopathy	0.000916	0.00428	CcSEcCtD
Ponatinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000912	0.00426	CcSEcCtD
Ponatinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000903	0.00421	CcSEcCtD
Ponatinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000895	0.00418	CcSEcCtD
Ponatinib—Erythema—Lisinopril—dilated cardiomyopathy	0.000889	0.00415	CcSEcCtD
Ponatinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000889	0.00415	CcSEcCtD
Ponatinib—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000868	0.00405	CcSEcCtD
Ponatinib—Back pain—Lisinopril—dilated cardiomyopathy	0.00086	0.00401	CcSEcCtD
Ponatinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000855	0.00399	CcSEcCtD
Ponatinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000841	0.00392	CcSEcCtD
Ponatinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000838	0.00391	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000835	0.0039	CcSEcCtD
Ponatinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000834	0.00389	CcSEcCtD
Ponatinib—Pain—Furosemide—dilated cardiomyopathy	0.000827	0.00386	CcSEcCtD
Ponatinib—Constipation—Furosemide—dilated cardiomyopathy	0.000827	0.00386	CcSEcCtD
Ponatinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000822	0.00384	CcSEcCtD
Ponatinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000796	0.00371	CcSEcCtD
Ponatinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000791	0.00369	CcSEcCtD
Ponatinib—Cough—Lisinopril—dilated cardiomyopathy	0.000776	0.00362	CcSEcCtD
Ponatinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000765	0.00357	CcSEcCtD
Ponatinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000765	0.00357	CcSEcCtD
Ponatinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000757	0.00353	CcSEcCtD
Ponatinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000757	0.00353	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000752	0.00351	CcSEcCtD
Ponatinib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00074	0.00346	CcSEcCtD
Ponatinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000726	0.00339	CcSEcCtD
Ponatinib—Infection—Lisinopril—dilated cardiomyopathy	0.000721	0.00336	CcSEcCtD
Ponatinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000711	0.00332	CcSEcCtD
Ponatinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000705	0.00329	CcSEcCtD
Ponatinib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000702	0.00327	CcSEcCtD
Ponatinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000694	0.00324	CcSEcCtD
Ponatinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000684	0.00319	CcSEcCtD
Ponatinib—ABCB1—heart—dilated cardiomyopathy	0.000684	0.00563	CbGeAlD
Ponatinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000662	0.00309	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000661	0.00309	CcSEcCtD
Ponatinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000656	0.00306	CcSEcCtD
Ponatinib—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000652	0.00304	CcSEcCtD
Ponatinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000647	0.00302	CcSEcCtD
Ponatinib—Dizziness—Furosemide—dilated cardiomyopathy	0.00064	0.00298	CcSEcCtD
Ponatinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000639	0.00298	CcSEcCtD
Ponatinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000631	0.00294	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000627	0.00292	CcSEcCtD
Ponatinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000626	0.00292	CcSEcCtD
Ponatinib—Pain—Lisinopril—dilated cardiomyopathy	0.000621	0.0029	CcSEcCtD
Ponatinib—Constipation—Lisinopril—dilated cardiomyopathy	0.000621	0.0029	CcSEcCtD
Ponatinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000615	0.00287	CcSEcCtD
Ponatinib—Rash—Furosemide—dilated cardiomyopathy	0.00061	0.00285	CcSEcCtD
Ponatinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000609	0.00284	CcSEcCtD
Ponatinib—Headache—Furosemide—dilated cardiomyopathy	0.000606	0.00283	CcSEcCtD
Ponatinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000593	0.00277	CcSEcCtD
Ponatinib—Nausea—Furosemide—dilated cardiomyopathy	0.000574	0.00268	CcSEcCtD
Ponatinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000574	0.00268	CcSEcCtD
Ponatinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000574	0.00268	CcSEcCtD
Ponatinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000521	0.00243	CcSEcCtD
Ponatinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000513	0.0024	CcSEcCtD
Ponatinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000497	0.00232	CcSEcCtD
Ponatinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.00048	0.00224	CcSEcCtD
Ponatinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000461	0.00215	CcSEcCtD
Ponatinib—Rash—Lisinopril—dilated cardiomyopathy	0.000458	0.00214	CcSEcCtD
Ponatinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000457	0.00213	CcSEcCtD
Ponatinib—Headache—Lisinopril—dilated cardiomyopathy	0.000455	0.00212	CcSEcCtD
Ponatinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000431	0.00201	CcSEcCtD
Ponatinib—SRC—Disease—NPPA—dilated cardiomyopathy	5.31e-05	0.000138	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.3e-05	0.000137	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.28e-05	0.000137	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.28e-05	0.000137	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—EGFR—dilated cardiomyopathy	5.27e-05	0.000137	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—RAF1—dilated cardiomyopathy	5.27e-05	0.000136	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.24e-05	0.000136	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—RAC1—dilated cardiomyopathy	5.22e-05	0.000135	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—RAF1—dilated cardiomyopathy	5.15e-05	0.000133	CbGpPWpGaD
Ponatinib—SRC—Disease—PSEN2—dilated cardiomyopathy	5.15e-05	0.000133	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	5.14e-05	0.000133	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—EGFR—dilated cardiomyopathy	5.13e-05	0.000133	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CD36—dilated cardiomyopathy	5.11e-05	0.000132	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—RAF1—dilated cardiomyopathy	5.06e-05	0.000131	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—RAF1—dilated cardiomyopathy	5.06e-05	0.000131	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	5.05e-05	0.000131	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—TNF—dilated cardiomyopathy	5.02e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.01e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.01e-05	0.00013	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCR3—dilated cardiomyopathy	5e-05	0.000129	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	5e-05	0.000129	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	5e-05	0.000129	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD36—dilated cardiomyopathy	5e-05	0.000129	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—RAF1—dilated cardiomyopathy	5e-05	0.000129	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	4.99e-05	0.000129	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—RAF1—dilated cardiomyopathy	4.99e-05	0.000129	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—RAF1—dilated cardiomyopathy	4.98e-05	0.000129	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.97e-05	0.000129	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.97e-05	0.000129	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—RAF1—dilated cardiomyopathy	4.96e-05	0.000128	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.91e-05	0.000127	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD36—dilated cardiomyopathy	4.91e-05	0.000127	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD36—dilated cardiomyopathy	4.9e-05	0.000127	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.9e-05	0.000127	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—RAF1—dilated cardiomyopathy	4.88e-05	0.000126	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—RAF1—dilated cardiomyopathy	4.86e-05	0.000126	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	4.85e-05	0.000125	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.84e-05	0.000125	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—RAC1—dilated cardiomyopathy	4.81e-05	0.000125	CbGpPWpGaD
Ponatinib—LYN—Immune System—ITGB1—dilated cardiomyopathy	4.81e-05	0.000124	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.8e-05	0.000124	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.79e-05	0.000124	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—EGFR—dilated cardiomyopathy	4.78e-05	0.000124	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	4.78e-05	0.000124	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	4.76e-05	0.000123	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.76e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—RAC1—dilated cardiomyopathy	4.71e-05	0.000122	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.66e-05	0.000121	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD36—dilated cardiomyopathy	4.66e-05	0.000121	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.65e-05	0.00012	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD36—dilated cardiomyopathy	4.65e-05	0.00012	CbGpPWpGaD
Ponatinib—KIT—Immune System—RAC1—dilated cardiomyopathy	4.63e-05	0.00012	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—RAC1—dilated cardiomyopathy	4.62e-05	0.00012	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	4.57e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—RAF1—dilated cardiomyopathy	4.54e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.51e-05	0.000117	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.5e-05	0.000117	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—RAC1—dilated cardiomyopathy	4.43e-05	0.000115	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.41e-05	0.000114	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.41e-05	0.000114	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—RAF1—dilated cardiomyopathy	4.4e-05	0.000114	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—RAC1—dilated cardiomyopathy	4.39e-05	0.000114	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—RAC1—dilated cardiomyopathy	4.38e-05	0.000113	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	4.38e-05	0.000113	CbGpPWpGaD
Ponatinib—FGFR2—Disease—RAC1—dilated cardiomyopathy	4.35e-05	0.000113	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	4.33e-05	0.000112	CbGpPWpGaD
Ponatinib—KIT—Disease—RAC1—dilated cardiomyopathy	4.27e-05	0.000111	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.27e-05	0.000111	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AGT—dilated cardiomyopathy	4.23e-05	0.00011	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.22e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—EGFR—dilated cardiomyopathy	4.21e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR3—Disease—RAF1—dilated cardiomyopathy	4.19e-05	0.000109	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.14e-05	0.000107	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.1e-05	0.000106	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD36—dilated cardiomyopathy	4.1e-05	0.000106	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD36—dilated cardiomyopathy	4.08e-05	0.000106	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.07e-05	0.000105	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.06e-05	0.000105	CbGpPWpGaD
Ponatinib—FGFR1—Disease—RAC1—dilated cardiomyopathy	4.05e-05	0.000105	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—RAC1—dilated cardiomyopathy	4.04e-05	0.000105	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	4e-05	0.000104	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.97e-05	0.000103	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—RAF1—dilated cardiomyopathy	3.97e-05	0.000103	CbGpPWpGaD
Ponatinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	3.94e-05	0.000102	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.92e-05	0.000102	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—GPX1—dilated cardiomyopathy	3.91e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR4—Disease—EGFR—dilated cardiomyopathy	3.89e-05	0.000101	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—EGFR—dilated cardiomyopathy	3.88e-05	0.0001	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—EGFR—dilated cardiomyopathy	3.86e-05	0.0001	CbGpPWpGaD
Ponatinib—LYN—Immune System—RAC1—dilated cardiomyopathy	3.86e-05	0.0001	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—RAC1—dilated cardiomyopathy	3.86e-05	9.99e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.85e-05	9.98e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.85e-05	9.97e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	3.84e-05	9.95e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.84e-05	9.95e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—EGFR—dilated cardiomyopathy	3.84e-05	9.93e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CD36—dilated cardiomyopathy	3.81e-05	9.86e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	3.73e-05	9.65e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TNF—dilated cardiomyopathy	3.7e-05	9.57e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AGT—dilated cardiomyopathy	3.69e-05	9.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—EGFR—dilated cardiomyopathy	3.68e-05	9.52e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.66e-05	9.47e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.65e-05	9.44e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.61e-05	9.36e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.61e-05	9.36e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—RAF1—dilated cardiomyopathy	3.61e-05	9.35e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—EGFR—dilated cardiomyopathy	3.61e-05	9.35e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	3.6e-05	9.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.6e-05	9.33e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.6e-05	9.32e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—RAF1—dilated cardiomyopathy	3.54e-05	9.18e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.53e-05	9.14e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.51e-05	9.08e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	3.5e-05	9.07e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ITGB1—dilated cardiomyopathy	3.49e-05	9.03e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—EGFR—dilated cardiomyopathy	3.47e-05	8.99e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.47e-05	8.98e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	3.46e-05	8.96e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AGT—dilated cardiomyopathy	3.43e-05	8.87e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—EGFR—dilated cardiomyopathy	3.43e-05	8.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—EGFR—dilated cardiomyopathy	3.42e-05	8.85e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	3.41e-05	8.84e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	3.4e-05	8.8e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.39e-05	8.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.37e-05	8.73e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.36e-05	8.7e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD36—dilated cardiomyopathy	3.36e-05	8.7e-05	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.36e-05	8.69e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.31e-05	8.57e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.29e-05	8.52e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.28e-05	8.5e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.25e-05	8.42e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	3.25e-05	8.42e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	3.24e-05	8.38e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.22e-05	8.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.2e-05	8.28e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.2e-05	8.28e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—RAF1—dilated cardiomyopathy	3.19e-05	8.26e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	3.17e-05	8.2e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—RAC1—dilated cardiomyopathy	3.17e-05	8.2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.16e-05	8.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.14e-05	8.13e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.14e-05	8.12e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.13e-05	8.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—RAF1—dilated cardiomyopathy	3.12e-05	8.09e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—EGFR—dilated cardiomyopathy	3.11e-05	8.06e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—RAF1—dilated cardiomyopathy	3.07e-05	7.94e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—RAF1—dilated cardiomyopathy	3.06e-05	7.93e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.05e-05	7.88e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	3.02e-05	7.81e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	3e-05	7.77e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RAC1—dilated cardiomyopathy	2.99e-05	7.74e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.99e-05	7.73e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.97e-05	7.7e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD36—dilated cardiomyopathy	2.97e-05	7.7e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—RAF1—dilated cardiomyopathy	2.94e-05	7.6e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—RAC1—dilated cardiomyopathy	2.92e-05	7.57e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—RAF1—dilated cardiomyopathy	2.91e-05	7.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AGT—dilated cardiomyopathy	2.91e-05	7.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—RAF1—dilated cardiomyopathy	2.9e-05	7.52e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.9e-05	7.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—RAF1—dilated cardiomyopathy	2.88e-05	7.47e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.88e-05	7.46e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—EGFR—dilated cardiomyopathy	2.88e-05	7.44e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AGT—dilated cardiomyopathy	2.86e-05	7.4e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.84e-05	7.35e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—RAF1—dilated cardiomyopathy	2.83e-05	7.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RAC1—dilated cardiomyopathy	2.83e-05	7.33e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—RAC1—dilated cardiomyopathy	2.8e-05	7.26e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.78e-05	7.2e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.76e-05	7.16e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EGFR—dilated cardiomyopathy	2.72e-05	7.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.71e-05	7.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AGT—dilated cardiomyopathy	2.71e-05	7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—RAF1—dilated cardiomyopathy	2.69e-05	6.96e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—RAF1—dilated cardiomyopathy	2.68e-05	6.94e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.64e-05	6.83e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—RAC1—dilated cardiomyopathy	2.59e-05	6.7e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	2.58e-05	6.69e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—RAF1—dilated cardiomyopathy	2.56e-05	6.63e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—RAF1—dilated cardiomyopathy	2.56e-05	6.62e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	2.55e-05	6.6e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	2.52e-05	6.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	2.5e-05	6.47e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—EGFR—dilated cardiomyopathy	2.48e-05	6.41e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	2.47e-05	6.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.46e-05	6.37e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	2.39e-05	6.18e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.37e-05	6.14e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—dilated cardiomyopathy	2.36e-05	6.11e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.33e-05	6.04e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	2.27e-05	5.87e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.27e-05	5.87e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—dilated cardiomyopathy	2.19e-05	5.66e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—dilated cardiomyopathy	2.14e-05	5.54e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—dilated cardiomyopathy	2.1e-05	5.45e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.1e-05	5.44e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—RAF1—dilated cardiomyopathy	2.1e-05	5.43e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	2.05e-05	5.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.02e-05	5.23e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—dilated cardiomyopathy	2.01e-05	5.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.01e-05	5.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—dilated cardiomyopathy	2e-05	5.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—dilated cardiomyopathy	1.99e-05	5.15e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RAF1—dilated cardiomyopathy	1.98e-05	5.13e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—dilated cardiomyopathy	1.98e-05	5.12e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	1.96e-05	5.06e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—dilated cardiomyopathy	1.94e-05	5.03e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—RAF1—dilated cardiomyopathy	1.94e-05	5.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.88e-05	4.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RAF1—dilated cardiomyopathy	1.88e-05	4.86e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—RAF1—dilated cardiomyopathy	1.86e-05	4.81e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.85e-05	4.79e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—dilated cardiomyopathy	1.84e-05	4.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—dilated cardiomyopathy	1.84e-05	4.76e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.82e-05	4.7e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAC1—dilated cardiomyopathy	1.81e-05	4.69e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.8e-05	4.67e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—dilated cardiomyopathy	1.76e-05	4.55e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—dilated cardiomyopathy	1.75e-05	4.54e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	1.75e-05	4.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGT—dilated cardiomyopathy	1.73e-05	4.48e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—RAF1—dilated cardiomyopathy	1.72e-05	4.44e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	1.66e-05	4.29e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	1.62e-05	4.2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	1.6e-05	4.15e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	1.56e-05	4.04e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—dilated cardiomyopathy	1.44e-05	3.73e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	1.41e-05	3.64e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.4e-05	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.38e-05	3.58e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.36e-05	3.52e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—dilated cardiomyopathy	1.36e-05	3.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	1.36e-05	3.51e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—dilated cardiomyopathy	1.33e-05	3.44e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.32e-05	3.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.29e-05	3.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—dilated cardiomyopathy	1.29e-05	3.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.28e-05	3.32e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—dilated cardiomyopathy	1.27e-05	3.3e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.23e-05	3.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—dilated cardiomyopathy	1.2e-05	3.11e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—dilated cardiomyopathy	1.18e-05	3.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.15e-05	2.99e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	1.14e-05	2.94e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	9.31e-06	2.41e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	8.61e-06	2.23e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	8.38e-06	2.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—dilated cardiomyopathy	8.24e-06	2.13e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	7.55e-06	1.95e-05	CbGpPWpGaD
